A Phase 1/2a Dose Escalation Study of AST-OPC1 in Subjects With Subacute Cervical Spinal Cord Injury

Trial Profile

A Phase 1/2a Dose Escalation Study of AST-OPC1 in Subjects With Subacute Cervical Spinal Cord Injury

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 02 Oct 2017

At a glance

  • Drugs OPC 1 (Primary)
  • Indications Spinal cord injuries
  • Focus Adverse reactions; Proof of concept
  • Acronyms SCi-STAR; SCiSTAR
  • Sponsors Asterias Biotherapeutics
  • Most Recent Events

    • 02 Oct 2017 According to an Asterias Biotherapeutics media release, company intends to report 6-month data from Cohort 3 (AIS-A 20 million-cell cohort) and Cohort 4 (AIS-B 10 million-cell cohort) in early 2018 after the 6-month results are collected for the two cohorts.
    • 02 Oct 2017 According to an Asterias Biotherapeutics media release, company completed recruitment and dosing in four of the five planned study cohorts also company expects to complete enrollment for Cohort 5 this year.
    • 02 Oct 2017 New 12-month data from the first efficacy cohort presented in an Asterias Biotherapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top